2 Biotechs with Upside – 7/4

Biotech has been one of the most explosive sectors of the year. 

And it’ll get even better.

Combined with new innovation, demand for better treatment, pharmaceutical companies strengthening pipelines, a resurgence of M&A, and weight loss drug demand, biotech will continue to offer some of the most explosive opportunities.

Crypto 101

How to Turn $3 into Generational Wealth

crypto 101

The biggest gains in crypto come from being early and right. For a limited time, get expert info on the coin poised to soar as real-world assets flood onto the blockchain. It’s your chance to invest alongside the financial elite with just $3.

Discover the “$3 Secret” to this new crypto

Company: Eli Lilly (SYM: LLY)

Look at Eli Lilly (SYM: LLY), for example. It’s seeing so much demand for its obesity treatments, it’s about to spend another $5.3 billion to make even more. And, according to The Wall Street Journal, its Zepbound treatment is generating more than 74,800 prescriptions every week.

Better, that boom is far from over, with Goldman Sachs noting the obesity market will reach $100 billion by 2030. Plus, according to Morgan Stanley, the global market for obesity drugs could increase more than 15-fold by 2030.

Colonial Metals

The Hidden Anchor Investment of the Elite Revealed

There’s ONE investment that’s discreetly held by over 97.6% of the ultra wealthy. We’re talking about Gold…But what the wealthy elite won’t readily disclose, is the tax-free loophole they’re leveraging to invest in gold without deploying their own capital. To follow the trail of the smart money whales…

Click here to claim your free copy of the Gold Investment Guide.

While you can always trade Eli Lilly and Novo Nordisk on the news, smaller, down, but not out stocks like Viking Therapeutics could see big upside.

Company: Viking Therapeutics (SYM: VKTX)

For one, the company reported that the injectable form of its treatment helped patients lose up to 13.1% of their weight after 13 weeks in Phase 2 trials. The company also said the oral form of its treatment led to a weight loss of about 3.3% after 28 days in Phase 1 trials. 

Now, thanks to the success of Phase 1, the company has plans to initiate its Phase 2 oral drug trials later this year.

Helping, Morgan Stanley just initiated coverage of VKTX with an outperform rating and a price target of $105. That’s based on promising Phase 2 data for VKTX2735 and VK2809 for the treatment of obesity and NASH, respectively. 

The firm’s analyst pointed out that the two drug candidates are poised to tap into blockbuster market opportunities. The anticipation of near-term updates on these drugs is expected to contribute to further upside for Viking Therapeutics,” says Investing.com.

Paradigm Press

This Play on Elon Musk’s Next IPO Could be Bigger than Nvidia

In the last five years, Nvidia is up by more than 3,200%… Which is absolutely insane.

If you missed out on the AI boom…

And the massive gains from stocks like Nvidia…

Elon Musk is now giving you a second chance.

Click here now and I’ll show you how you could profit BEFORE it goes public.

deal of the month

best growth stocks


Bundle package – lifetime subscriptions for all products


Recent posts


Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.